Related Experiment Video
Updated: May 7, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Right ventricular diastolic impairment in patients with pulmonary arterial hypertension
Silvia Rain1, M Louis Handoko, Pia Trip
1Departments of Pulmonology (S.R., P.T., C.T.-J.G., N.W., P.E.P., A.V.-N., F.S.d.M.), Physiology (S.R., M.L.H., N.W., G.J.S., W.J.P., C.A.C.O., J.v.d.V., F.S.d.M.), Cardiology (M.L.H.), and Medical Physics (J.T.M.), VU University Medical Center/Institute for Cardiovascular Research, Amsterdam, the Netherlands; Université Paris-Sud, Le Kremlin-Bicêtre, France (P.D., C.G., M.H.); INSERM UMR 999, LabEx LERMIT, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France (P.D., C.G., M.H.); AP-HP, Hôpital de Bicêtre, Service de Pneumologie, DHU Thorax Innovation, Le Kremlin-Bicêtre, France (M.H.); Heart & Lung Transplant Unit, St. Vincent's Hospital and Victor Chang Cardiac Research Institute, Sydney, Australia (P.M.); Muscle Research Unit, Institute for Biomedical Research, University of Sydney, Sydney, Australia (C.d.R.); Sarver Molecular Cardiovascular Research Program, Department of Physiology, University of Arizona, Tucson (C.S., C.G.H., H.L.G.); and ICIN-The Netherlands Heart Institute, Utrecht, the Netherlands (J.v.d.V.).
Background:
The role of right ventricular (RV) diastolic stiffness in pulmonary arterial hypertension (PAH) is not well established. Therefore, we investigated the presence and possible underlying mechanisms of RV diastolic stiffness in PAH patients.
Methods And Results:
Single-beat RV pressure-volume analyses were performed in 21 PAH patients and 7 control subjects to study RV diastolic stiffness. Data are presented as mean ± SEM. RV diastolic stiffness (β) was significantly increased in PAH patients (PAH, 0.050 ± 0.005 versus control, 0.029 ± 0.003; P<0.05) and was closely associated with disease severity. Subsequently, we searched for possible underlying mechanisms using RV tissue of PAH patients undergoing heart/lung transplantation and nonfailing donors. Histological analyses revealed increased cardiomyocyte cross-sectional areas (PAH, 453 ± 31 μm² versus control, 218 ± 21 μm²; P<0.001), indicating RV hypertrophy. In addition, the amount of RV fibrosis was enhanced in PAH tissue (PAH, 9.6 ± 0.7% versus control, 7.2 ± 0.6%; P<0.01). To investigate the contribution of stiffening of the sarcomere (the contractile apparatus of RV cardiomyocytes) to RV diastolic stiffness, we isolated and membrane-permeabilized single RV cardiomyocytes. Passive tension at different sarcomere lengths was significantly higher in PAH patients compared with control subjects (>200%; Pinteraction <0.001), indicating stiffening of RV sarcomeres. An important regulator of sarcomeric stiffening is the sarcomeric protein titin. Therefore, we investigated titin isoform composition and phosphorylation. No alterations were observed in titin isoform composition (N2BA/N2B ratio: PAH, 0.78 ± 0.07 versus control, 0.91 ± 0.08), but titin phosphorylation in RV tissue of PAH patients was significantly reduced (PAH, 0.16 ± 0.01 arbitrary units versus control, 0.20 ± 0.01 arbitrary units; P<0.05).
Conclusions:
RV diastolic stiffness is significantly increased in PAH patients, with important contributions from increased collagen and intrinsic stiffening of the RV cardiomyocyte sarcomeres.
More Related Videos
07:38Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension
Published on: January 20, 2023
09:40Induction of Right Ventricular Failure by Pulmonary Artery Constriction and Evaluation of Right Ventricular Function in Mice
Published on: May 13, 2019
Related Concept Videos
Mitral Stenosis I: Introduction
Mitral Regurgitation I: Introduction
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Heart Failure II: Pathophysiology
Cardiomyopathy IV: Restrictive Cardiomyopathy
Heart Failure III: Clinical Manifestations